VANCOUVER, BC, Feb. 1, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has received approval from Health Canada for its experiential training study that will test the safety and clinical efficacy of whole…

Source

Previous articlePharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
Next articleThe Agenda for Economic Analyses of Psychedelic-assisted Therapy